In the November 15 issue of The ASCO Post, the article, “Strong Showing for Ado-Trastuzumab Emtansine in Advanced HER2-Positive Heavily Pretreated Breast Cancer,” contained the following errors in the reported outcomes data for the TH3RESA trial:
- The article incorrectly stated the median survival in the control arm at the first interim analysis; this finding was actually 14.9 months.
- The any-grade adverse event rates included in the article were incorrect. These should be 94% for those who received ado-trastuzumab emtansine (Kadcyla) vs 89% for the control arm.
The ASCO Post regrets the errors. A corrected version of the article appears at
www.ascopost.com. ■
